Skip to content
10-Q

Quarterly Report

ULTRAGENYX PHARMACEUTICAL INC. RARE

0000950170-25-103290

← back to feed
Filed
Aug 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Jul 31, 2025 96.37M sh
Shares Diluted Q2 2025 · Jun 30, 2025 98.46M sh
Shares Diluted Q2 2025 · Jun 30, 2025 97.38M sh
Shares Diluted Q2 2025 · Jun 30, 2024 86.58M sh
Shares Diluted Q2 2025 · Jun 30, 2024 85.43M sh
Capex Q2 2025 · Jun 30, 2025 $3.78M
Capex Q2 2025 · Jun 30, 2024 $5.22M
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$274.75M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$267.69M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $176.31M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $173.73M
Cash And Equivalents Q2 2025 · Jun 30, 2024 $480.69M
Stockholders Equity Q2 2025 · Jun 30, 2025 $151.29M
Stockholders Equity Q2 2025 · Mar 31, 2025 $144.25M
Stockholders Equity Q2 2025 · Dec 31, 2024 $255.3M
Stockholders Equity Q2 2025 · Jun 30, 2024 $432.42M
Stockholders Equity Q2 2025 · Mar 31, 2024 $140.26M
Stockholders Equity Q2 2025 · Dec 31, 2023 $275.41M
Current Liabilities Q2 2025 · Jun 30, 2025 $293.24M
Current Liabilities Q2 2025 · Dec 31, 2024 $344.15M
Total Liabilities Q2 2025 · Jun 30, 2025 $1.15B
Total Liabilities Q2 2025 · Dec 31, 2024 $1.24B
Current Assets Q2 2025 · Jun 30, 2025 $719.79M
Current Assets Q2 2025 · Dec 31, 2024 $817.12M
Total Assets Q2 2025 · Jun 30, 2025 $1.31B
Total Assets Q2 2025 · Dec 31, 2024 $1.5B
Eps Diluted Q2 2025 · Jun 30, 2025 −$1.17
Eps Diluted Q2 2025 · Jun 30, 2025 −$2.73
Eps Diluted Q2 2025 · Jun 30, 2024 −$1.52
Eps Diluted Q2 2025 · Jun 30, 2024 −$3.54
Eps Basic Q2 2025 · Jun 30, 2025 −$1.17
Eps Basic Q2 2025 · Jun 30, 2025 −$2.73
Eps Basic Q2 2025 · Jun 30, 2024 −$1.52
Eps Basic Q2 2025 · Jun 30, 2024 −$3.54
Sga Expense Q2 2025 · Jun 30, 2025 $86.65M
Sga Expense Q2 2025 · Jun 30, 2025 $174.44M
Sga Expense Q2 2025 · Jun 30, 2024 $80.6M
Sga Expense Q2 2025 · Jun 30, 2024 $158.76M
Rd Expense Q2 2025 · Jun 30, 2025 $164.74M
Rd Expense Q2 2025 · Jun 30, 2025 $330.51M
Rd Expense Q2 2025 · Jun 30, 2024 $161.5M
Rd Expense Q2 2025 · Jun 30, 2024 $339.99M
Net Income Q2 2025 · Jun 30, 2025 −$114.95M
Net Income Q2 2025 · Jun 30, 2025 −$266.03M
Net Income Q2 2025 · Jun 30, 2024 −$131.6M
Net Income Q2 2025 · Jun 30, 2024 −$302.28M
Operating Income Q2 2025 · Jun 30, 2025 −$107.89M
Operating Income Q2 2025 · Jun 30, 2025 −$250.83M
Operating Income Q2 2025 · Jun 30, 2024 −$116.36M
Operating Income Q2 2025 · Jun 30, 2024 −$281.71M
Revenue Q2 2025 · Jun 30, 2025 $166.5M
Revenue Q2 2025 · Jun 30, 2025 $305.79M
Revenue Q2 2025 · Jun 30, 2024 $147.03M
Revenue Q2 2025 · Jun 30, 2024 $255.86M